|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| | | A conversation with Aki Ko, CEO, Elixirgen Therapeutics |  | The company uses a mobile manufacturing system to produce autologous stem cell therapy for patients with dyskeratosis congenita and other telomere biology disorders. | 
 | 
 | 
|  | 
|  | 
|  | 
| | |  |  | Systematic Approach to Enhancing iPSC Expansion |  | Webinar | Eppendorf SE |  | Learn how stirred-tank bioreactors can optimize hiPSC cultures, achieving over 10× higher cell density while retaining viability — ideal for drug discovery, disease modeling, and regenerative therapies. | 
 | 
 | 
|  | 
|  | 
| | |  |  | Adapting A rcAAV Assay For Commercial Manufacturing |  | White Paper | By Oxana M. Tsygankova, Ph.D., Leann Walsh, Lana Sweet, and Dana Cipriano, and Brian Tomkowicz, Ph.D., SK pharmteco |  | Better understand the intricacies of AAV triple transfection and how advances in vector production and cell line optimization are enhancing gene therapy. | 
 | 
 | 
|  | 
| | |  |  | Leverage qPCR And dPCR To Streamline Biologics Development |  | Article | Applied Biosystems by Thermo Fisher Scientific, qPCR |  | PCR methods that deliver high-quality results throughout biologics development and biomanufacturing can help biologics manufacturers bridge the gap from basic research to clinical trials and manufacturing. | 
 | 
 | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| | |  |  | 
 |  | It's no secret that on-going research aims to improve the efficacy and specificity of non-viral approaches for genetic engineering. But the field is rapidly evolving with research aimed at improving transfection efficiency, targeting, and safety profiles of non-viral delivery systems. Join Cell & Gene Live to discuss the most notable approaches and recent breakthroughs as well as promising non-viral vectors used in clinical trials. Attendance is free thanks to the support of MaxCyte. | 
 | 
 | 
| | | Connect With Cell & Gene: | 
 | 
 | 
|  |